These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 4652156

  • 21. [Principles for amantadine therapy in parkinsonism].
    Gilland O.
    Lakartidningen; 1972 Nov 08; 69(46):5343-5. PubMed ID: 4650743
    [No Abstract] [Full Text] [Related]

  • 22. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 08; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 23. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 08; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 24. [The trial of intravenous L-DOPA in patients with Parkinson's disease].
    Nardini M, Fieschi C, Agnoli A, Arcioli I, Zanette E.
    Riv Neurol; 1970 Jun 08; 40(2):75-85. PubMed ID: 5429003
    [No Abstract] [Full Text] [Related]

  • 25. Augmenting the action of levodopa.
    Rao SK, Vakil SD, Calne DB, Hilson A.
    Postgrad Med J; 1972 Nov 08; 48(565):653-6. PubMed ID: 4568331
    [Abstract] [Full Text] [Related]

  • 26. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U, Schönfelder H.
    Nervenarzt; 1972 Oct 08; 43(10):531-2. PubMed ID: 4628192
    [No Abstract] [Full Text] [Related]

  • 27. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M, Jorgensen PB.
    Aust N Z J Med; 1972 Aug 08; 2(3):252-5. PubMed ID: 4564049
    [No Abstract] [Full Text] [Related]

  • 28. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
    Ambrosetto C, Martinelli P.
    Minerva Med; 1971 Oct 31; 62(82):4017-9. PubMed ID: 5125069
    [No Abstract] [Full Text] [Related]

  • 29. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W, Danielcyk W, Neumayer E, Riederer P.
    J Neural Transm; 1973 Oct 31; 34(2):133-43. PubMed ID: 4722571
    [No Abstract] [Full Text] [Related]

  • 30. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
    Kluzer G, Lampo B.
    Minerva Med; 1971 Oct 31; 62(82):4013-4. PubMed ID: 5125067
    [No Abstract] [Full Text] [Related]

  • 31. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E, Cerillo A, Tata MR, Decina A.
    Acta Neurol (Napoli); 1973 Oct 31; 28(2):208-12. PubMed ID: 4709076
    [No Abstract] [Full Text] [Related]

  • 32. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R, Kvan L, Presthus J, Thoresen GB.
    Acta Neurol Scand Suppl; 1972 Oct 31; 51():121-2. PubMed ID: 4514336
    [No Abstract] [Full Text] [Related]

  • 33. [Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
    Fieschi C, Casacchia M, Nardini M, Reitano N.
    Minerva Med; 1971 Oct 31; 62(82):4040-2. PubMed ID: 5125075
    [No Abstract] [Full Text] [Related]

  • 34. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS, Bauer RB, Rosenbaum H.
    Geriatrics; 1971 Aug 31; 26(8):61-70. PubMed ID: 5096462
    [No Abstract] [Full Text] [Related]

  • 35. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
    Raspa EG, Paciaroni E, Saccomanno G.
    Minerva Med; 1971 Oct 31; 62(82):4031-5. PubMed ID: 5125073
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ.
    N Y State J Med; 1974 Jan 31; 74(1):47-51. PubMed ID: 4591989
    [No Abstract] [Full Text] [Related]

  • 37. [The therapeutic association of L-dopa and amantadine. Preliminary results in a group of patients with Parkinson's disease].
    Gomirato G, Perfetti C.
    Riv Neurobiol; 1970 Jan 31; 16(3):247-54. PubMed ID: 5518838
    [No Abstract] [Full Text] [Related]

  • 38. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H.
    Ugeskr Laeger; 1974 Feb 11; 136(7):377. PubMed ID: 4821980
    [No Abstract] [Full Text] [Related]

  • 39. Amantadine versus L-2 dopa and amatadine plus L-dopa.
    Fieschi C, Nardini M, Casacchia M, Tedone ME, Reitano M, Robotti E.
    Lancet; 1970 Jul 18; 2(7664):154-5. PubMed ID: 4194541
    [No Abstract] [Full Text] [Related]

  • 40. L-dopa and amantadine in the therapy of parkinsonism.
    Weeth JB, Shealy CN, Mercier DA.
    Wis Med J; 1969 Nov 18; 68(11):325-8. PubMed ID: 4901055
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.